In this Healio video exclusive, Michael V. Chiorean, MD, explains that physicians can safely and “with confidence” switch patients with inflammatory bowel disease from an originator biologic to a biosimilar at any point during treatment.
“We can now say with confidence, while certainly this isn’t necessarily the way most of us practice, that you can switch to a biosimilar at any given time, during induction and/or maintenance and unrelated to the disease activity at the time of switching,” Chiorean, co-director of the Inflammatory Bowel Disease Center at Swedish